uniQure stock sees analyst targets diverge at USD 23.14
Published on 10/08/2026 at 10:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
uniQure (ISIN NL0010696654) stock was last at USD 23.14 on Nasdaq on October 7, 2026 at 4:00 p.m. ET, up 0.35 percent from the prior close of USD 23.06. The latest analyst reset came on October 5, when MarketBeat reported that Barclays cut its target from USD 60 to USD 28.
Analyst targets split sharply
The Barclays move contrasts with the wider target picture. According to Stock Analysis, 12 analysts carried a Strong Buy consensus and an average target of USD 62.55 as of October 5, 2026.
The average target stands 170.31 percent above the USD 23.14 share price. The published target range ran from USD 28.08 to USD 91.83, showing how widely estimates differ after the latest AMT-130 data.
Quarterly figures show the tradeoff
uniQure's second-quarter 2026 numbers combined higher revenue with a deeper per-share loss. On July 29, 2026, MarketBeat reported revenue of USD 5.84 million against a USD 5.45 million consensus estimate.
The same quarter produced an EPS loss of USD 1.22, compared with a consensus loss of USD 0.82 and a loss of USD 0.69 in the year-earlier quarter. The revenue beat did not offset the earnings miss in the latest reported period.
AMT-130 remains the central driver
uniQure's investor-relations page lists additional Phase I/II data for ifezuntirgene inilparvovec, also known as AMT-130, released on September 29, 2026. The uniQure update concerns Huntington's disease and follows the company's September submission of a biologics license application.
That clinical program sits beside a business with limited current revenue and substantial cash use. The finance statements show second-quarter operating cash flow of negative USD 28.576 million and a net loss of USD 81.059 million for the period ended June 30, 2026.
Stock stays below its yearly high
QURE's USD 23.14 price on October 7, 2026 was 67.64 percent below its 52-week high of USD 71.50 and above its 52-week low of USD 8.73. Market capitalization stood at USD 1.6 billion, while trading volume reached 1,752,888 shares on the same date.
uniQure stock facts
- Company: uniQure N.V.
- ISIN: NL0010696654
- Ticker: QURE
- Trading venue: Nasdaq
- Price (as of October 7, 2026, 4:00 p.m. ET): USD 23.14
- Market capitalization: USD 1.6 billion (as of October 7, 2026)
- 52-week range: USD 8.73-71.50 (as of October 7, 2026)
- Sector / Industry: Healthcare / Biotechnology
More news and analysis on uniQure stock can be found on the uniQure stock topic page.
